Acrivon Therapeutics, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Acrivon Therapeutics, Inc. Common Stock carries a market capitalization of 76.92M, placing it among publicly traded companies globally. Its enterprise value stands at -11.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 76.92M |
| Enterprise Value | -11.58M |
Share Statistics
Acrivon Therapeutics, Inc. Common Stock currently has 42.85M shares outstanding.
| Shares Outstanding | 42.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | -1.15 |
| P/OCF Ratio | -1.12 |
Financial Position
Acrivon Therapeutics, Inc. Common Stock maintains a current ratio of 7.99, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.99 |
| Quick Ratio | 7.86 |
| Debt / Equity | 2.44 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -64.63 |
| Return on Assets (ROA) | -57.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Acrivon Therapeutics, Inc. Common Stock's stock has declined approximately -6.51042% over the past 52 weeks. The 50-day moving average sits at 1.98, while the 200-day moving average is 1.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.51042% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.79 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -76.87M, while operating income came in at -78.37M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -78.37M |
| Pretax Income | -74.22M |
| Net Income | -74.22M |
| EBITDA | -76.87M |
| EBIT | -78.37M |
| Earnings Per Share (EPS) | -1.87 |
Balance Sheet
Acrivon Therapeutics, Inc. Common Stock holds 89.96M in cash and equivalents against 2.12M in total debt, resulting in a net debt position of -41.42M. Total book value stands at 86.67M, with working capital of 80.05M providing operational flexibility.
| Cash & Cash Equivalents | 89.96M |
| Total Debt | 2.12M |
| Net Debt | -41.42M |
| Equity (Book Value) | 86.67M |
| Book Value Per Share | 2.02 |
| Working Capital | 80.05M |
Cash Flow
Acrivon Therapeutics, Inc. Common Stock produced -62.92M in operating cash flow over the past twelve months. After subtracting -1.22M in capital expenditures, free cash flow totaled -64.14M - equivalent to -1.62 per share.
| Operating Cash Flow | -62.92M |
| Capital Expenditures | -1.22M |
| Free Cash Flow | -64.14M |
| FCF Per Share | -1.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.08 |
| FCF Yield | -87.29 |
Scores
Acrivon Therapeutics, Inc. Common Stock posts an Altman Z-Score of -2.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.36 |